Curriculum Vitae

Personal information

Aurélie Beauvois

Work experience

1. Employer: Sciensano

- Start date: 102024
- End date:
- Position: Quality assessor
- Activities: Quality assessor for biological medicines: Assessment of scientific dossiers (registrations (MAA), variations, scientific advices) and participation in inspections (pharmaceutical companies) for biological medicines (vaccines, plasma_derived products, biotech products).
- Country: Belgium

Education and training

1.Subject: PhD in Bioengineering (Gembloux Agro-Bio Tech, University of Liège)

- Start date: 102020
- End date: 0912024
- Qualification: PhD in Bioengineering
- Institution: Gembloux Agro-Bio Tech, University of Liège
- Country: Belgium
- Skills: Molecular biology, virology, immunology, genetics, biotechnology, cell biology.

2.Subject: Master in Bioengineering: chemistry and bio-industries (Gembloux Agro-Bio Tech, University of Liège)

- Start date: 092018
- End date: 092020
- Qualification: Master in Bioengineering, chemistry and bio-industries
- Institution: Gembloux Agro-Bio Tech, University of Liège
- Country: Belgium
- Skills: General training programme: chemistry, physics, mathematics, biology and biotechnology.

Additional information

Publications

Publication in scientific journal as first authorship

- Beauvois, A. *et al.* The helicase-like transcription factor redirects the autophagic flux and restricts human T cell leukemia virus type 1 infection. *Proc. Natl. Acad. Sci. U. S. A.* **120**, e2216127120 (2023).

Projects

Memberships

Oral presentations at international scientific conferences:

- "The helicase-like transcription factor restricts the infectious cycle of HTLV-1 but interferes with T-cell mediated antiviral cytotoxicity" at the international conference on HTLV-1 in London, United-Kingdom (June 2024)
- "The helicase-like transcription factor (HLTF) inhibits infectious replication of HTLV-1" at the international conference on HTLV-1 in Melbourne, Australia (May 2022)

Posters:

- "The helicase-like transcription factor restricts the infectious cycle of HTLV-1 but interferes with T-cell mediated antiviral cytotoxicity" at the international conference on HTLV-1 in London, United-Kingdom (June 2024) =>Best poster award
- "The helicase-like transcription inhibits infectious replication of the human T cell leukemia virus type 1 infection" at the GIGA-Cancer Day 2022 (September 2022) => Best poster award

Other Relevant Information